日本臨牀 77/増刊1 心不全(第2版)中

出版社: 日本臨牀社
発行日: 2019-02-28
分野: 臨床医学:一般  >  雑誌
ISSN: 00471852
雑誌名:
特集: 心不全(第2版)中
電子書籍版: 2019-02-28 (第2版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

19,800 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

19,800 円(税込)

目次

  • 特集 心不全(第2版)中

    IX.治療の進歩
     1.ガイドライン
     2.治療ストラテジー
     3.最近の臨床試験

    X.薬物治療概論
     1.心不全治療薬の使い方:総論
     2.ACE阻害薬
     3.ARB(アンジオテンシン受容体拮抗薬)
     4.β遮断薬
     5.ミネラルコルチコイド受容体拮抗薬
     6.利尿薬
     7.バソプレシンV2受容体拮抗薬
     8.ジギタリス製剤
     9.カテコールアミン製剤
     10.PDE III阻害薬
     11.Ca2+感受性増強薬
     12.心房性ナトリウム利尿ペプチド

    XI.研究・開発中の薬物治療
     1.慢性心不全に対するベリシグアトの治療効果
     2.Omecamtiv Mecarbil
     3.SGLT2阻害薬:エンパグリフロジン、カナグリフロジン、ダパグリフロジンなど

    XII.デバイス治療
     1.心臓再同期療法(CRT/CRT-D)
     2.ICD
     3.心不全のモニタリングデバイス

    XIII.補助循環・外科療法
     1.心不全の外科療法:総論
     2.大動脈内バルーンパンピング(IABP)・経皮的心肺補助法(PCPS)
     3.補助人工心臓(VAD)
     4.左室形成術・僧帽弁関連手術
     5.心臓移植の適応
     6.心臓移植(小児)
     7.心臓移植(成人)の実際
     8.移植後の内科管理
     9.僧帽弁形成術
     10.大動脈弁閉鎖不全症に対する大動脈弁形成術

    XIV.血液浄化療法
     1.体外限外濾過法(ECUM)を用いた急性血液浄化療法
     2.心不全における持続的静脈静脈血液濾過法(CVVH)
     3.持続的血液濾過透析(CHDF)

    XV.輸液療法
     1.心不全患者への輸液療法-高齢者,合併症など-

    XVI.非薬物療法
     1.運動療法
     2.心不全における呼吸補助療法
     3.緩和ケア
     4.栄養療法

    XVII.心不全の予後
     1.予後
     2、心不全の予後予測因子とは

    XVIII.心不全の危険因子・予防
     1.危険因子
     2.心不全の予防
     3.心不全を誘発・増悪させる薬剤

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

IX 治療の進歩

P.17 掲載の参考文献
1) Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 26 : 1376-1398, 1995.
2) Writing committee members, Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
3) Yancy CW, et al : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136 : e137-e161, 2017.
4) Writing committee members, Yancy CW, et al : 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure : An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 134 : e282-293, 2016.
P.24 掲載の参考文献
1) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
P.32 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン急性・慢性心不全診療ガイドライン (2017年改訂版).
P.38 掲載の参考文献
1) 日本循環器学会 : 循環器疾患診療実態調査報告書 (2017年度実施・公表). [http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2016web.pdf] (2019年1月閲覧)
2) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年1月閲覧)
3) 日本心臓リハビリテーション学会 心臓リハビリテーション標準プログラム策定部会 : 心不全の心臓リハビリテーション標準プログラム (2017年版). [http://www.jacr.jp/web/wp-content/uploads/2015/04/shinfuzen2017_2.pdf] (2019年1月閲覧)
P.45 掲載の参考文献
1) Writing Committee Members, et al : Yancy CW, 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
2) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版).
5) Koelling TM, et al : Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 144 : 524-529, 2002.
6) Obadia JF, et al : Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med, 2018. [Epub ahead of print] (doi : 10.1056/NEJMoa1805374)
12) Yumino D : Home Medica Care for Heart Failure. Yakugaku Zassi 136 : 1133-1136, 2016.
14) Bohm M, et al : Fluid status telemedicine alerts for heart failure : a randomized c ontrolled trial. Eur Heart J 37 : 3154-3163, 2016.
P.52 掲載の参考文献
1) Okamoto H, et al : Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol : Japanese chronic heart failure (J-CHF) study. Int J Cardiol 164 : 238-244, 2013.
5) McAlister FA, et al : Meta-analysis : beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150 : 784-794, 2009.
7) Paolillo S, et al : Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. Eur J Heart Fail 19 : 904-914, 2017.
8) Kitakaze M, et al : Safety and tolerability of once-daily controlled-release carvedilol 10-80 mg in Japanese patients with chronic heart failure. Circ J 76 : 668-674, 2012.
9) Kotecha D, et al : Efficacy of β blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis. Lancet 384 : 2235-2243, 2014.
12) Nagatomo Y, et al : Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol-Insights From Japanese Chronic Heart Failure (J-CHF) Study. Circ J 82 : 691-698, 2018.
13) Nagatomo Y, et al : Presence of autoantibody directed against β1-adrenergic receptors is associated with amelioration of cardiac function in response to carvedilol : Japanese Chronic Heart Failure (JCHF) Study. J Card Fail 21 : 198-207, 2015.
P.59 掲載の参考文献
6) Yamamoto K, et al : Effects of carvedilol on heart failure with preserved ejection fraction : the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15 : 110-118, 2013.
9) El-Refai M, et al : Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. J Card Fail 19 : 73-79, 2013.
11) Yamamoto K, et al : Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction-a report from the Japanese Diastolic Heart Failure Study (J-DHF). J Cardiol 63 : 424-431, 2014.
P.66 掲載の参考文献
1) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
P.73 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版).
2) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
5) Tsutsui H, et al ; for the J-EMPHASIS-HF Study Group : Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF). Circ J 82 : 148-158, 2018.
P.78 掲載の参考文献
P.85 掲載の参考文献
1) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
2) Writing Committee Members ; Yancy CW, et al : 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure : An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 134 : e282-293, 2016.
7) Vodovar N, et al : Neprilysin, cardiovascular, and Alzheimer's diseases : the therapeutic split? Eur Heart J 36 : 902-905, 2015.
P.90 掲載の参考文献
3) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
4) Yancy CW, et al : 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure : An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 134 : e282-293, 2016.
P.97 掲載の参考文献
8) Wegner M, et al : Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Cardiovasc Res 31 : 891-898, 1996.
P.105 掲載の参考文献
P.110 掲載の参考文献
4) McAlister FA, et al : Meta-analysis : beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150 : 784-794, 2009.
5) Flannery G, et al : Analysis of randomized controiled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101 : 865-869, 2008.
7) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet 353 : 9-13, 1999.
8) Lechat P, et al : Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103 : 1428-1333, 2001.
11) Yancy CW, et al : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136 : e137-e161, 2017.
P.120 掲載の参考文献
3) Matsuzaki M, et al : Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics : a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25 (Suppl 1) : S33-45, 2011.
7) Matsue Y, et al : Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. J Card Fail 22 : 423-432, 2016.
14) Inomata T, et al : Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment-Results From the K-STAR Study. Circ J 82 : 159-167, 2017.
18) Kinugawa K, et al : Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J 78 : 844-852, 2014.
P.127 掲載の参考文献
8) Matsue Y, et al : Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. J Card Fail 22 : 423-432, 2016.
P.134 掲載の参考文献
5) ADVANCE Collaborative Group, et al : Intensive blood giucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 : 2560-2572, 2008.
18) Davies MJ, et al : Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 : 2669-2701, 2018.
20) Onuma Y, et al : Differences in coronary risk factors, procedural characteristics, mortality and stent thrombosis between two all-comers percutaneous coronary intervention registries from Europe and Japan : a patient-level data analysis of the Bern-Rotterdam and j-Cypher registries. EuroIntervention 11 : 533-540, 2015.
23) Frier BM : Hypoglycaemia in diabetes mellitus : epidemi ology and clinical implications. Nat Rev Endocrinol 10 : 711-722, 2014.
P.140 掲載の参考文献
P.146 掲載の参考文献
6) Fitchett D, et al : Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high ardiovascular risk : results of the EMPA-REG OUTCOME trial. Eur Heart J 37 : 1526-1534, 2016.
8) Tanaka H, et al : Factors Affecting Canagliflozin-lnduced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. Adv Ther 34 : 436-451, 2017.
P.152 掲載の参考文献
P.160 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版).
2) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
3) Yancy CW, et al : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 : 776-803, 2017.
P.168 掲載の参考文献
1) White WB, et al : Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 378 : 1200-1210, 2018.
3) Choi H, et al : New Perspectives in Rheumatology : Implicationsa of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis Rheumatol 70 : 1702-1709, 2018.
5) Kuwabara M : Febuxostat does not increase all-cause mortality and cardiovascular mortality compared with placebo from FEATHER study. Arthritis Rheumatol, 2018. [Epub ahead of print] (doi : 10.1002/art.40744)
6) Kojima S, et al : FREED-Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. ESC Congress 2018 Late Breaking Session, 2018. [https://esc365.escardio.org/Congress/ESC-Congress-2018/Hot-Line-Session-4/181440-freed-febuxostat-for-cerebral-and-cardiorenovascular-events-prevention-study] (2019年1月閲覧)
8) MacDonald TM, et al : Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST) : a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open 4 : e005354, 2014.
P.172 掲載の参考文献
2) Leyva F, et al : Uric acid in chronic heart failure : a marker of chronic inflammation. Eur Heart J 19 : 1814-1822, 1998.
3) Leyva F, et al : Uric acid in chronic heart failure : a measure of the anaerobic threshold. Metab Clin Exp 47 : 1156-1159, 1998.
4) Cicoira M, et al : Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 143 : 1107-1111, 2002.
6) Doehner W, et al : Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure : results from 2 placebocontrolled studies. Circulation 105 : 2619-2624, 2002.
7) Farquharson CA, et al : Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106 : 221-226, 2002.
9) Cappola TP, et al : Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104 : 2407-2411, 2001.
10) Gavin AD, Struthers AD : Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91 : 749-753, 2005.
11) Cingolani HE, et al : The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients : La Plata Study. J Card Fail 12 : 491-498, 2006.
P.178 掲載の参考文献
2) Leier CV, et al : Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 67 : 817-822. 1983.
3) Elkayam U, et al : Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation 99 : 2652-2657, 1999.
4) Franciosa JA, et al : Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med 69 : 559-566, 1980.
6) Zakeri R, et al : Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial : rationale and design. Circ Heart Fail 8 : 221-228, 2015.
P.182 掲載の参考文献
3) 筒井裕之, ほか : 急性・慢性心不全診療ガイドライン (2017年改訂版). 日本循環器学会/日本心不全学会合同ガイドライン.
4) Kotecha D, et al : Efficacy ofβblockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis. Lancet 384 : 2235-2243, 2014.
8) 奥村謙, ほか ; 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2010-2011年度合同研究班報告) カテーテルアブレーションの適応と手技に関するガイドライン, 2012. [http://www.j-circ.or.jp/guideline/pdf/JCS2012_okumura_h.pdf]
P.189 掲載の参考文献
P.195 掲載の参考文献
1) Tamburro P, Wilber D : Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 124 : 1035-1045, 1992.
2) Keber L, et al : Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 375 : 1221-1230, 2016.
4) Strickberger SA, et al : Amiodarone versus implantable cardioverter-defibrillator : randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 41 : 1707-1712, 2003.
6) Bardy GH, et al : Amiodarone or an impiantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 : 225-237, 2005.
7) Bristow MR, et al : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 : 2140-2150, 2004.
P.200 掲載の参考文献
1) Goldschlager N, et al : Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 160 : 1741-1748, 2000.
2) Kowey PR, et al : Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 92 : 3255-3263, 1995.
3) Scheinman MM, et al : Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 92 : 3264-3272, 1995.
5) 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告) : 不整脈の非薬物治療ガイドライン (2011年改訂版).
P.208 掲載の参考文献
1) Perel A, et al : Effectiveness of CPAP by mask for pulmonary edema associated with hypercarbia. Intensive Care Med 9 : 17-19, 1983.
5) van de Borne P, et al : Effect of Cheyne-Stokes respiration on muscle sympathetic nerve activity in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 81 : 432-436, 1998.
9) Bradley TD, Floras JS : Adaptive Servo-Ventilation for Central Sleep Apnea in Heart Failure. N Engl J Med 374 : 687-691, 2016.
11) Woehrle H, et al : Adaptive servo ventilation for central sleep apnoea in heart failure : SERVE-HF on-treatment analysis. Eur Respir J 50 : 2017. (doi : 10.1183/13993003.01692-2016)
14) O'Connor CM, et al : Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure : The CAT-HF Trial. J Am Coll Cardiol 69 : 1577-1587, 2017.
P.213 掲載の参考文献
2) Mortara A, et al : Arterial baroreflex modulation of heart rate in chronic heart failure : clinical and hemodynamic correlates and prognostic implications. Circulation 96 : 3450-3458, 1997.
3) Fauchier L, et al : Heart rate variability in idiopathic dilated cardiomyopathy : characteristics and prognostic value. J Am Coll Cardiol 30 : 1009-1014, 1997.
6) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全ガイドライン (2017年改訂版).
10) Premchand RK, et al : Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure : results of the ANTHEM-HF trial. J Card Fail 20 : 808-816, 2014.
12) Gold MR, et al : Vagus Nerve Stimulation for the Treatment of Heart Failure : The INOVATE-HF Trial. J Am Coll Cardiol 68 : 149-158, 2016.
14) Zhang Y, et al : Relationship between right cervical vagus nerve stimulation and atrial fibrillation inducibility : therapeutic intensities do not increase arrhythmogenesis. Heart Rhythm 6 : 244-250, 2009.
P.219 掲載の参考文献
8) Mehra MR, et al : A tale of the twist in the outflow graft : An analysis from the MOMENTUM 3 trial. J Heart Lung Transplant 37 : 1281-1284, 2018.

X 薬物治療概論

P.229 掲載の参考文献
2) Nagai R, et al : Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction : comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J 77 : 908-916, 2013.
5) Yancy CW, et al : 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment : Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction : A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 71 : 201-230, 2018.
9) Solomon SD, et al : Angiotensin Receptor Neprilysin Inhibiti on in Heart Failure With Preserved Ejection Fraction : Rationale and Design of the PARAGON-HF Trial. JACC Heart Fail 5 : 471-482, 2017.
10) Tsuji K, et al : Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 19 : 1258-1269, 2017.
13) Koh AS, et al : A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 19 : 1624-1634, 2017.
P.237 掲載の参考文献
2) Hokimoto S, et al : Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 94 : 1513-1518, 1996.
4) 日本循環器学会・日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版), p35, 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2018年12月閲覧)
5) CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
11) 高齢者の安全な薬物療法ガイドライン 2015 (日本老年医学会編), p22-92, メジカルビュー, 2015. [https://www.jpn-geriat-soc.or.jp/info/topics/pdf/20170808_01.pdf] (2018年12月閲覧)
12) Yoshimura M, et al : B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 112 : 716-720, 2002.
P.243 掲載の参考文献
1) CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
3) Pfeffer MA, et al : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 : 669-677, 1992.
4) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 : 821-828, 1993.
6) Flather MD, et al : Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction : a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355 : 1575-1581, 2000.
7) Vasan RS, Levy D : Defining diastolic heart failure : a call for standardized diagnostic criteria. Circulation 101 : 2118-2121, 2000.
10) Mancini DM, et al : Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 85 : 1364-1373, 1992.
11) Mancini DM, et al : In vivo magnetic resonance spectroscopy measurement of deoxymyoglobin during exercise in patients with heart failure. Demonstration of abnormal muscle metabolism despite adequate oxygenation. Circulation 90 : 500-508, 1994.
12) Aplacebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group. J Am Coll Cardiol 2 : 755-763, 1983.
15) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
P.249 掲載の参考文献
1) Donoghue M, et al : A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 : E1-9, 2000.
3) Ferrario CM, et al : Counterregulatory actions of angiotensin- (1-7). Hypertension 30 : 535-541, 1997.
4) Vickers C, et al : Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Boil Chem 277 : 14838-14843, 2002.
5) Santos RA, et al : Angiotensin- (1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100 : 8258-8263, 2003.
8) Cohn JN, Tognoni G : A randomized trial of the angiotensin-receptor bl ocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
9) Pfeffer MA, et al : Effects of candesartan on mortality and morbidity in paitients with chronic heart failure : the CHARM-Overall programme. Lancet 362 : 759-766, 2003.
14) Dickstein K, Kjekshus J : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 : 752-760, 2002.
15) Pfeffer MA, et al : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 : 1893-1906, 2003.
P.254 掲載の参考文献
1) WRITING COMMITTEE MEMBERS, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
3) SPRINT Research Group, et al : A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373 : 2103-2116, 2015.
4) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編) : 高血圧治療ガイドライン 2014. ライフサイエンス出版, 2014.
14) Bakris GL, et al : Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine : is this a cause for concern? Arch Intern Med 160 : 685-693, 2000.
P.263 掲載の参考文献
2) Cannavo A, Koch WJ : Targeting β3-Adrenergic Receptors in the Heart : Selective Agonism and β-Blockade. J Cardiovasc Pharmacol 69 : 71-78, 2017.
3) Mangmool S, Linke WA : Therapeutic Targets for Treatment of Heart Failure : Focus on GRKs and β-Arrestins Affecting βAR Signaling. Front Pharmacol 9 : 1336, 2018. (doi : 10.3389/fphar. 2018.01336)
4) Hamdani N, et al : Alteration of the beta-adrenergic signaling pathway in human heart failure. Curr Pharm Biotechnol 13 : 2522-2531, 2012.
5) Gorelik J, et al : Spatial control of the βAR system in heart failure : the transverse tubule and beyond. Cardiovasc Res 98 : 216-224, 2013.
7) Wang J, et al : Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling. Nat Commun 8 : 1706, 2017.
8) Nakaya M, et al : Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways. J Biol Chem 287 : 35669-35677, 2012.
P.268 掲載の参考文献
2) Eichhorn EJ, Bristow MR : Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 94 : 2285-2296, 1996.
5) McAlister FA, et al : Meta-analysis : beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150 : 784-794, 2009.
6) Andersson B, et al : Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol. Eur Heart J 20 : 575-583, 1999.
7) Lechat P, et al : Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 96 : 2197-2205, 1997.
11) Kotecha D, et al : Efficacy of β blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis. Lancet 384 : 2235-2243, 2014.
13) Desai RV, et al : Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving β-blockers : insights from the BEST trial. Int J Cardiol 163 : 61-67, 2013.
14) Witte KK, et al : Mortality reduction associated with β-adrenoceptor inhibition in chronic heart failure is greater in patients with diabetes. Diabetes Care 41 : 136-142, 2018.
15) Metra M, et al : Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail 9 : 901-909, 2007.
16) Lund LH, et al : Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 312 : 2008-2018, 2014.
P.274 掲載の参考文献
2) Yamamuro M, et al : Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. Circ J 72 : 1346-1350, 2008.
5) Nagoshi T, et al : Optimization of cardiac metabolism in heart failure. Curr Pharm Des 17 : 3846-3853, 2011.
6) Ohtani T, et al : Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure : Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 292 : R946-954, 2007.
10) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
14) Tsutsui H, et al : Double-Blind, Randomized Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). Circ J 82 : 148-158, 2017.
15) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版).
P.280 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン ; 筒井裕之, ほか : 急性・慢性心不全診療ガイドライン (2017年改訂版).
2) 松崎益徳, ほか : 慢性心不全治療ガイドライン (2010年改訂版).
3) 木原康樹, ほか : 高齢心不全患者の治療に関するステートメント, 2016.
5) Savarese G, et al : Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction : an analysis of l 1215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20 : 1326-1334, 2018.
7) Fukuta H, et al : Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction : a meta-analysis of randomized controlled trials. Heart Vessels, 2018. [Epub ahead of print] (doi : 10.1007/s00380-018-1279-1)
9) 山本一博, ほか : 心不全患者における栄養評価・管理に関するステートメント (日本心不全学会ガイドライン委員会編), 2018.
11) Lofman I, et al : Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure. J Am Heart Assoc 7 : e009359, 2018. (doi : 10.1161/JAHA.118.009359)
P.287 掲載の参考文献
P.293 掲載の参考文献
1) Wilcox CS. et al : Na+, K+, and BP homeostasis in man during furosemide : effects of prazosin and captopril. Kidney Int 31 : 135-141, 1987.
6) Chen HH, et al : Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction : the ROSE acute heart failure randomized trial. JAMA 310 : 2533-2543, 2013.
P.300 掲載の参考文献
6) Cowley AW, et al : Effect of renal medullary circulation on arterial pressure. J Hypertens Suppl 10 : S187-193, 1992.
7) Imamura T, et al : Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. Circ J 77 : 397-404, 2013.
8) Mori T, et al : Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis. Adv Perit Dial 29 : 33-37, 2013.
9) Mori T, et al : Role of Chronic Use of Tolvaptan in Patients with Heart Failure Undergoing Peritoneal Dialysis. Adv Perit Dial 32 : 39-45, 2016.
P.307 掲載の参考文献
1) Ishikawa S : Is exaggerated release of arginine vasopressin an endocrine disorder? Pathophysiology and treatment. J Clin Med 6 : E102, 2017. (doi : 10.3390/jcm6110102)
2) Sawyer WH, et al : Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 212 : 49-51, 1981.
3) Manning M, et al : Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1- (beta-mercapto-beta, beta-pentamethylenepropionic acid), 2-D-isoleucine, 4- valine] arginine-vasopressin at position 4. J Med Chem 27 : 423-429, 1984.
4) 石川三衛 : バゾプレッシンV2拮抗薬. 循環器科 34 : 27-33, 1993.
5) Yamamura Y, et al : OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 252 : 572-574, 1991.
7) Yamamura Y, et al : OPC-41061, a highly potent human vasopressin V2-receptor antagonist : pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287 : 860-867, 1998.
12) Fujisawa G, et al : Therapeutic efficacy of non-peptide ADH antagonist OPC31260 in SIADH rats. Kidney Int 44 : 19-23, 1993.
13) Xu DL, et al : Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 99 : 1500-1505, 1997.
14) Tsuboi Y, et al : Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 46 : 237-244, 1994.
P.315 掲載の参考文献
3) Preeti J, Ellison DH : Chronic Heart Failure and Comorbid Renal Dysfunction-A Focus on Type 2 Cardiorenal Syndrome. Curr Cardiol Rev 12 : 186-194, 2016.
8) Wilcox CS, et al : Na+, K+, and BP homeostasis in man during furosemide : effects of prazosin and captopril. Kidney Int 31 : 135-141, 1987.
9) Imamura T, et al : Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients-association between non-responders and chronic kidney disease. Circ J 77 : 397-404, 2013.
10) Inomata T, et al : Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment-Results From the K-STAR Study. Circ J 82 : 159-167, 2017.
P.320 掲載の参考文献
1) Smith TW : Digitalis. Mechanisms of action and clinical use. N Engl J Med 318 : 358-365, 1988.
1) Uretsky BF, et al : Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure : results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 22 : 955-962, 1993.
2) Writing Committee Members ; Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
3) Gheorghiade M, et al : Digoxin. A neurohormonal modulator in heart failure? Circulation 84 : 2181-2186, 1991.
4) Rubinow A, et al : Digoxin sensitivity in amyloid cardiomyopathy. Circulation 63 : 1285-1288, 1981.
P.325 掲載の参考文献
P.329 掲載の参考文献
1) A O'Connor CM, et al : Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure : insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (1 Pt 1) : 78-86, 1999.
2) Bellomo R, et al : Low-dose dopamine in patients with early renal dysfunction : a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356 : 2139-2143, 2000.
3) De Backer D, et al : Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 : 779-789, 2010.
4) Stoner JD 3rd, et al : Comparison of dobutamine and dopamine in treatment of severe heart failure. Br Heart J 39 : 536-539, 1977.
P.335 掲載の参考文献
1) Kondo T, et al : Specialty-Related Differences in the Acute-Phase Treatment and Prognosis in Patients With Acute Heart Failure-Insights From REALITY-AHF. Circ J, 2018. [Epub ahead of print]
4) Steen PA, et al : Efficacy of dopamine, dobutamine, and epinephrine during emergence from cardiopulmonary bypass in man. Circulation 57 : 378-384, 1978.
5) Colucci WS, et al : Adrenergic overload and apoptosis in heart failure : implications for therapy. J Card Fail 6 (2 Suppl 1) : 1-7, 2000.
7) Unverferth DV, et al : Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 100 : 622-630, 1980.
8) Liang CS, et al : Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation 69 : 113-119, 1984.
9) Unverferth DV, et al : The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J 106 : 29-34, 1983.
14) Adamopoulos S, et al : Effects of pulsed beta-stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure. Lancet 345 : 344-349, 1995.
15) Oliva F, et al : Intermittent 6-month low-dose dobutamine infusion in severe heart failure : DICE multicenter trial. Am Heart J 138 : 247-253, 1999.
16) Bellomo R, et al : Low-dose dopamine in patients with early renal dysfunction : a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356 : 2139-2143, 2000.
18) Chen HH, et al : Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction : the ROSE acute heart failure randomized trial. JAMA 310 : 2533-2543, 2013.
19) De Backer D, et al : Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 : 779-789, 2010.
21) Desjars P, et al : Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 17 : 426-429, 1989.
24) Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : executive summary : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : 1810-1852, 2013.
25) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
26) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2018年11月閲覧)
P.341 掲載の参考文献
2) 角尾道夫, ほか : 静脈内持続投与試験. 薬理と治療 21 : 4659-4679, 1993.
3) 日本透析医学会雑誌 23 : 275-283, 2008.
4) 新博次, ほか : 新しい強心薬E-1020の臨床第I相試験 (1) -静脈内投与試験. 臨床薬理 21 : 613-621, 1990.
5) 酒井兼司, ほか : 社内資料 代謝物の検討試験.
6) 重松昭生, ほか : 抗心不全薬Pimobendan (UD-CG 115 BS) カプセルの第I相臨床試験-1.25 mg, 2.5 mg, 5.0 mg, 7. 5 mg単回経口投与-. 臨牀と研究 68 : 2154-2172, 1991.
7) 角尾道夫, ほか : Pimobendan (UD-CG 115 BS) の第I相臨床試験-連続経口投与試験-. 臨牀と研究 68 : 3515-3538, 1991.
8) 林博史, ほか : 忌性心不全に対するPimobendan (UD-CG 115 BS) の臨床効果. Therapeutic Research 13 : 591-612, 1992.
9) Costanzo MR, et al : The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure : a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J 154 : 267-277, 2007.
11) Kubo SH, et al : Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 85 : 942-949, 1992.
P.343 掲載の参考文献
2) Stevenson LW : Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1 : 251-257, 1999.
8) Edelson J, et al : Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation 73 : III145-152, 1986.
10) Amenomori H, et al : Phosphodiesterase III inhibitor olprinone chlorate is not significantly removed by continuous venovenous hemodiafiltration. ASAIO J 46 : 635-638, 2000.
P.348 掲載の参考文献
P.353 掲載の参考文献
1) Verdouw PD, et al : Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 126 : 21-30, 1986.
2) Pouleur H, et al : Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure. J Cardiovasc Pharmacol 14 (Suppl 2) : S18-22, 1989.
3) Permanetter B, et al : Acute effects of intravenous UDCG 115 BS (pimobendan) on the cardiovascular system and left ventricular pump function. J Cardiovasc Pharmacol 14 (Suppl 2) : S36-40, 1989.
4) Ruegg JC : Effects of new inotropic agents on Ca++sensitivity of contractile proteins. Circulation 73 (3 Pt 2) : III78-84, 1986.
5) Fujino K, et al : Sensitization of dog and guinea pig heart myofilaments to Ca2+activation and the inotropic effect of pimobendan : comparison with milrinone. Circ Res 63 : 911-922, 1988.
6) Solaro RJ, et al : The positive inotropic effect of pimobendan involves stereospecific increases in the calcium sensitivity of cardiac myofilaments. J Cardiovasc Pharmacol 14 (Suppl 2) : S7-12, 1989.
8) Katz SD, et al : A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 123 : 95-103, 1992.
9) Kubo SH, et al : Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 85 : 942-949, 1992.
11) Murai K, et al : Efficacy and limitations of oral inotropic agents for the treatment of chronic heart failure. Int Heart J 54 : 75-81, 2013.
13) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
P.357 掲載の参考文献
3) 医薬品インタビューフォーム, ハンプ注射用 1000, 2017年5月改訂 (第11版). [https://www.medicallibrary-dsc.info/di/hanp_for_injection_1000/pdf/if_hnp_1705_11.pdf] (2019年1月閲覧)
5) 添付文書. ハンプ注射用 1000, 2014年1月改訂 (第14版). [https://www.medicallibrary-dsc.info/di/hanp_for_injection_1000/pdf/pi_hnp_1401.pdf] (2019年1月閲覧)
10) 急性・慢性心不全診療ガイドライン (2017年改訂版), 日本循環器学会/日本心不全学会合同ガイドライン. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年1月閲覧)
11) 配合変化一覧表, ハンプ注射用 1000, 2014年10月改訂. [https://www.medicallibrary-dsc.info/di/hanp_for_injection_1000/pdf/hai_hnp_1410.pdf] (2019年1月閲覧)
P.361 掲載の参考文献
1) 筒井裕之, ほか : 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版).
4) Stevenson LW : Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1 : 251-257, 1999.
9) Nomura F, et al : Multicenter prospective investigation on efficacy and safety of carperitide as a firstline drug for acute heart failure syndrome with preserved blood pressure : COMPASS : Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ J 72 : 1777-1786, 2008.
P.365 掲載の参考文献
2) Kitakaze M. et al : Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND) : two randomised trials. Lancet 370 : 1483-1493, 2007.
3) Sezai A, et al : Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting : the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol 55 : 1844-1851. 2010.
5) Mentzer RM, et al : Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery : the NAPA Trial. J Am Coll Cardiol 49 : 716-726, 2007.
7) Sezai A, et al : Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting : the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol 58 : 897-903, 2011.
9) Sward K, et al : Recombinant human atrial natriuretic peptide in ischemic acute renal failure : a randomized placebo-controlled trial. Crit Care Med 32 : 1310-1315, 2004.
11) Sezai A, et al : Carperitide and atrial fibrillation after coronary bypass grafting : the Nihon University working group study of low-dose HANP infusion therapy during cardiac surgery trial for postoperative atrial fibrillation. Circ Arrhythm Electrophysiol 8 : 546-553, 2015.

XI 研究・開発中の薬物治療

P.373 掲載の参考文献
3) Koka S, Kukreja RC : Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil : A Long Acting Phosphodiesterase-5 Inhibitor. Mol Cell Pharmacol 2 : 173-178, 2010.
5) Krishnan SM, et al : The Impact of the Nitric Oxide (NO) /Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease : A Preclinical Perspective. Int J Mol Sci 19 : pii : E1712, 2018.
10) Filippatos G, et al : Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail 19 : 782-791, 2017.
P.377 掲載の参考文献
8) Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF : Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure). [https://clinicaltrials.gov/ct2/show/NCT02929329] (2019年1月閲覧)
P.382 掲載の参考文献
6) Wiviott SD, et al : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 2018. [Epub ahead of print] (doi : 10.1056/NEJMoa1812389)
10) Liu T, et al : Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res 115 : 44-54, 2014.
12) Ferrannini E, et al : CV Protection in the EMPA-REG OUTCOME Trial : A "Thrifty Substrate" Hypothesis. Diabetes Care 39 : 1108-1114, 2016.
13) Sano M : A new class of drugs for heart failure : SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol 71 : 471-476, 2018.

XII デバイス治療

P.392 掲載の参考文献
1) Aranda JM, et al : Cardiac resynchronization therapy in patients with heart failure and conduction abnormalities other than left bundle-branch block : analysis of the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Clin Cardiol 27 : 678-682, 2004.
3) Bristow MR, et al : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 : 2140-2150, 2004.
6) Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac resynchronization therapy in heart failure with narrow QRS complexes. N Eng J Med 2007 ; 357 : 2461-2471.
9) Varma N, et al : Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. J Am Heart Assoc 7 : 2018.
11) Lindenfeld J, et al : Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 115 : 204-212, 2007.
18) Leclercq C, et al : Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure : The RD-CHF Study. Pacing Clin Electrophysiol 30 (Suppl 1) : S23-30, 2007.
27) Fantoni C, et al : Right and left ventricular activation sequence in patients with heart failure and right bundle branch block : a detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol 16 : 112-119 ; discussion 120-121, 2005.
P.402 掲載の参考文献
2) Seo Y, et al : The role of echocardiography in predicting responders to cardiac resynchronization therapy. Circ J 75 : 1156-1163, 2011.
6) Helm H, et al : Cardiac dyssynchrony analysis using circumferential versus longitudinal strain : implications for assessing cardiac resynchronization. Circulation 111 : 2760-2767, 2005.
7) Seo Y, et al : Left ventricular activation imaging by 3-dimensional speckle-tracking echocardiography. Comparison with electrical activation mapping. Circ J 77 : 2481-2489, 2013.
9) Prinzen FW, et al : Mapping of regional myocardial strain and work during ventricular pacing : experimental study using magnetic resonance imaging tagging. J Am Coll Cardiol 33 : 1735-1742, 1999.
11) Sugano A, et al : Cardiac resynchronization therapy in a patient with a failing systemic right ventricle. Can J Cardiol 31 : 819. e5-7, 2015.
P.408 掲載の参考文献
6) AL-Khatib SM, et al : 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm 15 : e73-e189, 2018. (doi : 10.1016/j.hrthm.2017.10.036)
7) 奥村謙, ほか : 不整脈の非薬物治療ガイドライン (2011年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf] (2018年12月閲覧)
17) Tanno K, et al : Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J 69 : 19-22, 2005.
19) Buxton AE, et al : Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 342 : 1937-1945, 2000.
22) Kawashiro N, et al : Clinical characteristics and outcome of hospitalized patients with congestive heart failure : results of the HIJC-HF registry. Circ J 72 : 2015-2020, 2008.
23) Shiba M, Shimokawa H : Chronic heart failure in Japan : implications of the CHART studies. Vasc Health Risk Manag 4 : 103-113, 2008.
P.415 掲載の参考文献
4) JCS Joint Working Group : Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmiag. (JCS 2011). Circ J 77 : 249-274, 2013.
5) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
11) Tsuchihashi K, et al : Transient left ventricular apical ballooning without coronary artery stenosis : a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol 38 : 11-18, 2001.
13) Sasaki S, et al : Usefulness of the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circ J 78 : 2987-2989, 2014.
16) Schmidinger H : The implantable cardioverter defibrillator as a "bridge to transplant" : a viable clinical strategy? Am J Cardiol 83 : 151D-157D, 1999.
18) Waβnig NK, et al : Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death. Circulation 134 : 635-643, 2016.
19) 日本不整脈学会WCDワーキンググループ : 着用型自動除細動器 (WCD) の臨床使用に関するステートメント (2015年4月改訂). [http://new.jhrs.or.jp/pdf/guideline/statement201505_01.pdf] (2019年1月閲覧)
20) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年1月閲覧)
25) Duncker D, et al : Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study. J Am Heart Assoc 6 : e004512, 2017. (doi : 10.1161/JAHA.116.004512)
P.420 掲載の参考文献

XIII 補助循環・外科療法

P.427 掲載の参考文献
1) Nishimura RA, et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : 2438-2488, 2014.
3) Vergnat M, et al : Contemporary results of aortic valve repair for congenital disease : lessons for management and staged strategy. Eur J Cardiothorac Surg 52 : 581-587, 2017.
5) 松崎益徳, ほか : 慢性心不全治療ガイドライン (2010年改訂版). 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告). [http://www.j-circ.or.jp/guideline/pdf/JCS2010_matsuzaki_h.pdf] (2019年1月閲覧)
6) Wakasa S, et al : Estimating postoperative left ventricular volume : Identification of responders to surgical ventricular reconstruction. J Thorac Cardiovasc Sung 156 : 2088-2096, 2018. (doi : 10.1016/j.jtcvs.2018.06.090)
P.434 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
2) Weber KT, Janicki JS : Intraaortic balloon counterpulsation. A review of physiological principles, clinical results, and device safety. Ann Thorac Surg 17 : 602-636, 1974.
6) 大藤純 : 体外式膜型人工肺 (ECMO) の最近の進歩. 四国医学雑誌 73 : 207-220, 2017.
9) Pappalardo F, et al : Concomitant implantation of Impella on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail 19 : 404-412, 2017.
P.439 掲載の参考文献
1) 戸田宏一 : 体外設置型補助人工心臓. 体外循環と補助循環 第27回人工臓器学会教育セミナー (西村元延編), p81-88, 日本人人工臓器学会, 2011.
3) Kishimoto S, et al : Novel temporary left ventricular assist system with hydrodynamically levitated bearing pump for bridge to decision : initial preclinical assessment in a goat model. J Artif Organs 21 : 23-30, 2018.
P.444 掲載の参考文献
1) Yancy CW, et al : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 : 776-803, 2017.
2) Kinugawa K : How to treat stage D heart failure? -When to implant left ventricular assist devices in the era of continuous flow pumps? -. Circ J 75 : 2038-2045, 2011.
4) Imamura T, et al : Preoperative levels of bilirubin or creatinine adjusted by age can predict their reversibility after implantation of left ventricular assist device. Circ J 77 : 96-104, 2013.
7) Tabit CE, et al : Tumor necrosis factor-α levels and non-surgical bleeding in continuous-flow left ventricular assist devices. J Heart Lung Transplant 37 : 107-115, 2018.
8) Imamura T, et al : Omega-3 therapy is associated with reduced castrointestinal bleeding in patients with continuous-flow left ventricular assist device. Circ Heart Fail 11 : e005082, 2018.
P.450 掲載の参考文献
1) Otsuji Y, et al : Insights from three-dimentional echocardiography into the mechanism of functional mitral regurgitation : direct in vivo demonstration of altered leaflet tethering geometry. Circulation 96 : 1999-2008, 1997.
2) Nishimura RA, et al : 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 70 : 252-289, 2017.
3) Falk V, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 52 : 616-664, 2017.
4) Shingu Y, Matsui Y : Did we misunderstand how to calculate total stroke work in mitral regurgitation by echocardiography? Circ J 76 : 1533-1534, 2012.
5) 大北裕, ほか : 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版). 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告), p16-17, 2012.
9) Shingu Y, Matsui Y : How can we prevent functional mitral stenosis after surgery? J Thorac Cardiovasc Surg 140 : 251-252 ; author reply 252-253, 2010.
11) Matsui Y, et al : Papillary Muscle Tugging Approximation for Functional Mitral Regurgitation. anu Thorac Surg 2018. (doi : https://doi.org/10.1016/j.athoracsur.2018.11.072)
14) Warwick R, et al : Mathematical modelling to identify patients who should not undergo left ventricle remodelling surgery. Interact Cardiovasc Thorac Surg 10 : 661-665, 2010.
16) Wakasa S, et al : Risk scores for predicting mortality after surgical ventricular reconstruction for ischemic cardiomyopathy : results of a Japanese multicenter study. J Thorac Cardiovasc Surg 147 : 1868-1874, 1874, e1-2, 2014.
P.455 掲載の参考文献
1) 日本心臓移植研究会 : 日本の心臓移植レジストリ「心臓移植の現状 20180831現在」, 2018 [http://www.jsht.jp/registry/japan/] (2018年12月閲覧).
P.463 掲載の参考文献
1) Voeller RK, et al : Trends in the indications and survival in pediatric heart transplants : a 24-year single-center experience in 307 patients. Ann Thorac Surg 94 : 807-815 ; discussion 815-816, 2012.
2) 福嶌教偉 : Pediatric heart transplantation. 小児循環器学会雑誌 30 : 403-414, 2016.
3) Michler RE, Reitz BA : Novel approach for orthotopic heart transplantation in visceroatrial situs inversus. Ann Thorac Surg 60 : 194-197, 1995.
7) Goldfarb SB, et al : The Registry of the International Society for Heart and Lung Transplantation : Eighteenth Official Pediatric Lung and Heart-Lung Transplantation Report-2015 ; Focus Theme : Early Graft Failure. J Hear Lung Transplant 34 : 1255-1263, 2015.
P.468 掲載の参考文献
1) Barnard CN : The operation. A human cardiac transplant : an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 41 : 1271-1274, 1967.
2) 日本心臓移植研究会 : 心臓移植レジストリ報告 (1999年2月~2018年8月31日 N=408例) [http://www.jsht.jp/registry/japan/] (2019年1月閲覧)
4) 日本移植学会 : 臓器移植ファクトブック 2017. [http://www.asas.or.jp/jst/pdf/factbook/factbook2017.pdf] (2019年1月閲覧)
5) 日本臓器移植ネットワーク : 心臓移植希望者 (レシピエント) 選択基準. [http://www.jotnw.or.jp/jotnw/law_manual/pdf/rec-heart.pdf] (2019年1月閲覧)
6) 日本臓器移植ネットワーク : 臓器提供者 (ドナー) 適応基準. [http://www.jotnw.or.jp/jotnw/law_manual/pdf/DonorAdjustmentStandard.pdf] (2019年1月閲覧)
7) 小野稔 : 心臓移植におけるマージナルドナーの可能性と限界. 移植 50 : 343-351, 2015.
8) 日本心臓血管外科学会 : 心臓血管外科手術の解説-心臓移植. [http://jscvs.umin.ac.jp/jscvs/syujutusyugitokaisetu_sinzou/5_3_sinzouisyoku_syujutu_sinzou_.html] (2019年1月閲覧)
9) Shumway NE, et al : Transplantation of the heart. Adv Surg 2 : 265-284, 1966.
10) Dreyfus G, et al : Total orthotopic heart transplantation : an alternative to the standard technique. Ann Thorac Surg 52 : 1181-1184, 1991.
11) Riberi A, et al : Systemic embolism : a serious complication after cardiac transplantation avoidable by bicaval technique. Eur J Cardiothorac Surg 19 : 307-311 ; discussion 311-312, 2001.
P.474 掲載の参考文献
2) 布田伸一 : 心臓移植における内科医の役割. 移植 50 : 112-117, 2015.
3) Fukushima N, et al : Registry Report on Heart Transplantation in Japan (June 2016). Circ J 81 : 298-303, 2017.
4) 布田伸一, ほか : 我が国における心臓移植免疫抑制療法 : 移植実施施設におけるプロトコール. 心臓移植 (松田暉監修, 布田伸一, 福嶌教偉編), p233-237, シュプリンガー・ジャパン (丸善), 2011.
5) Hammond EH, et al : Vascular (humoral) rejection in heart transplantation : pathologic observations and clinical implications. J Heart Transplant 8 : 430-443, 1989.
6) Hammond EH, et al : Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 11 (3 Pt 2) : S111-119, 1992.
8) 布田伸一, ほか : 心移植遠隔期における移植心冠動脈病変の検討. 脈管学 41 : 887-893, 2001.
12) Greenhalgh T, Hurwitz B (ed) : Narrative Based Medicine : Dialogue and Discourse in Clinical Practice, BMJ Books, London, 1998. [斎藤清二, ほか (監訳) : ナラティブ・ベイスト・メディスン-臨床における物語りと対話 (トリシャ・グリーンハル, ブライアン・ハーウィッツ編), 金剛出版, 2001.]
13) Nunoda S, et al : Switching to tacrolimus extended-release improved the effectiveness of immunosuppressive therapy in a heart transplant patient : A case report. J Cardiol Cases 6 : e26-e29, 2012.
P.481 掲載の参考文献
11) Messas E, et al : Chordal cutting : anew therapeutic approach for ischemic mitral regurgitation. Circulation 104 : 1958-1963, 2001.
14) Kincaid EH, et al : Anterior leaflet augmentation for ischemic mitral regurgitation. Ann Thorac Surg 78 : 564-568 ; discussion 568, 2004.
P.487 掲載の参考文献
1) Borer JS, et al : Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. Circulation 97 : 525-534, 1998.
2) Stugaard M, et al : Energy loss in the left ventricle obtained by vector now mapping as a new quantitative measure of severity of aortic regurgitation : a combined experimental and clinical study. Eur Heart J Cardiovasc Imaging 16 : 723-730, 2015.
3) Nitenberg A, et al : Coronary flow and resistance reserve in patients with chronic aortic regurgitation, angina pectoris and normal coronary arteries. J Am Coll Cardiol 11 : 478-486, 1988.
4) Nishirnura RA, et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : e57-185, 2014.
5) Chaliki HP, et al : Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation 106 : 2687-2693, 2002.
9) Desai ND, Christakis GT : Bioprosthetic aortic valve replacement : stented pericardial and porcine valves. In : Cardiac Surgery in the Adult, 3rd ed (ed by Cohn LH), p857-894, McGraw-Hill, New York, 2008.
13) Klodas E, et al : Optimizing timing of surgical correction in patients with severe aortic regurgitation : role of symptoms. J Am Coll Cardiol 30 : 746-752, 1997.

XIV 血液浄化療法

P.496 掲載の参考文献
4) Guazzi MD, et al : Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J 72 : 534-539, 1994.
5) Marenzi G, et al : Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 38 : 963-968, 2001.
8) Marenzi G, et al : Continuous ultrafiltration for congestive heart failure : the CUORE trial. J Card Fail 20 : 378. e1-9, 2014.
11) Damman K, et al : Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53 : 582-588, 2009.
13) Brisco MA, et al : Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies : Insights From the DOSE Trial. J Card Fail 22 : 753-760, 2016.
P.502 掲載の参考文献
1) Kramer P, et al : Arteriovenous haemofiltration : a new and simple method for treatment of over-hydrated patients resistant to diuretics. Klin Wochenschr 55 : 1121-1122, 1977,
2) 日本透析医学会 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌 38 : 1491-1501, 2005.
3) NKF-KDOQI : Clinidal Practice Guidelines for Vascular Access, Update 2006. In : 2006 Updates Clinical Practice Guidelines and Recommendations, National Kidney Foundation, 2006.
4) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版).
5) 笠岡俊志 : 持続的血液濾過透析. 徹底ガイド心不全 Q&A-プレホスピタルから慢性期まで-, p185-189, 総合医学社, 2013.
6) 吉本広平, 土井研人 : 循環器管理を極める 体液管理における血液浄化療法. 循環器ジャーナル 66 (4) : 589-595, 2018.
P.507 掲載の参考文献
1) 中北朋, ほか : 特集 血液浄化療法を科学する, 血液透析療法, 血液濾過療法, 血液透析濾過療法. Clinical Engineering 26 : 341-346, 2015.
2) 花房規男 : 特集 血液浄化療法を科学する, 持続的腎代替療法. Clinical Engineering 26 : 363-372, 2015.
3) 篠田俊雄 : 特集 血液浄化療法 : 基礎の基礎, 血液透析・血液濾過とその応用. Clinical Engineering 19 : 359-363, 200&
4) 中敏夫, ほか : 持続血液浄化. 腎と透析 48 : 617-661, 2000.
5) 日本循環器学会/日本心不全学会合同ガイドライン ; 筒井裕之, ほか : 非薬物療法 急性血液浄化治療. 急性・慢性心不全診療ガイドライン (2017年改訂版).
6) 鈴木正司 : バスキュラーアクセス. 透析療法マニュアル, p181-191, 日本メディカルセンター, 2014.
7) 鈴木尚紀, ほか : 集中治療業務の実際. 臨床工学プラクティカル・フルコース (川崎忠行編), p282-302, メジカルビュー社, 2015.

XV 輸液療法

P.515 掲載の参考文献

XVI 非薬物療法

P.524 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
3) Okita K, et al : Exercise intolerance in chronic heart failure-skeletal muscle dysfunction and potential therapies. Circ J 77 : 293-300, 2013.
4) 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版), 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告), 2013.
7) O'Connor CM, et al : Efficacy and safety of exercise training in patients with chronic heart failure : HF-ACTION randomized controlled trial. JAMA 301 : 1439-1450, 2009.
9) Chen LK, et al : Sarcopenia in Asia : consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15 : 95-101, 2014.
11) Kamiya K, et al : Prognostic usefulness of arm and calf circumference in patients ≧ 65 years of age with cardiovascular disease. Am J Cardiol 119 : 186-191, 2016. (doi 10.1010/j.amjcard.016.09.040)
12) 日本心臓リハビリテーション学会 心臓リハビリテーション標準プログラム策定部会 : 心不全の心臓リハビリテーション標準プログラム (2017年版).
13) Tsuchihashi-Makaya M, et al : Home-based disease management program to improve psychological status in patients with heart failure in Japan. Circ J 77 : 926-933, 2013.
P.530 掲載の参考文献
1) 日本循環器学会, ほか : 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版).
4) O'Connor CM, et al : Efficacy and safety of exercise training in patients with chronic heart failure : HF-ACTION randomized controlled trial. JAMA 301 : 1439-1450, 2009.
7) Tucker WJ, et al : Mechanisms of the improvement in peak VO2 with exercise training in heart failure with reduced or preserved ejection fraction. Heart Lung Circ 27 : 9-21, 2018.
11) 日本老年医学会 : フレイルに関する日本老年医学会からのステートメント, 2014.
12) Vigorito C, et al : Frailty and cardiac rehabilitation : A call to action from the EAPC Cardiac Rehabilitation Section. Eur J Prev Cardiol 24 : 577-590, 2017.
13) 日本心臓リハビリテーション学会 : 心不全の心臓リハビリテーション標準プログラム (2017年版). [http://www.jacr.jp/web/jacrreha/physician_system/program/] (2018年11月閲覧)
P.536 掲載の参考文献
1) 野原隆司, ほか : IX. 運動療法システムの構築 : 2. 退院後のリハビリテーションおよび疾病管理心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版), p119. [http://www.j-circ.or.jp/guideline/pdf/JCS2012_nohara_h.pdf] (2019年1月閲覧)
2) 長山雅俊, ほか : ドイツにおける心臓リハビリテーションの現況. 心臓リハビリテーション 8 : 207-212, 2003.
3) Jonsen AR, et al : 赤林朗, ほか (監訳) : 臨床倫理学 第5版, 新興医学出版社, p13, 2006.
5) Kato N, et al : Insufficient self-care is an independent risk factor for adverse clinical outcomes in Japanese patients with heart failure. Int Heart J 54 : 382-389, 2013.
6) Lainscak M, et al : Self-care management of heart failure : practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 13 : 115-126, 2011.
7) 長山雅俊, ほか : 急性心筋梗塞の医療連携パス-榊原記念病院-. 治療 90 (増刊 : 地域医療連携実践ガイドブック) : 968-977, 2008.
P.543 掲載の参考文献
2) Karlsdottir AE, et al : Hemodynamic responses during aerobic and resistance exercise. J Cardiopulm Rehabil 22 : 170-177, 2002.
3) Werber-Zion G, et al : Left ventricular function during strength testing and resistance exercise in patients with left ventricular dysfunction. J Cardiopulm Rehabil 24 : 100-109, 2004.
4) Meyer K, et al : Hemodynamic responses during leg press exercise in patients with chronic congestive heart failure. Am J Cardiol 83 : 1537-1543, 1999.
7) Piepoli MF, et al : Exercise training in heart failure : from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 13 : 347-357, 2011.
9) 高橋哲也, ほか : 心不全に対するレジスタンストレーニング. 循環器内科 69 : 252-258, 2011.
P.548 掲載の参考文献
1) 黒瀬聖司, ほか : 急性冠症候群患者の軽度狭窄病変に対する心臓リハビリテーションの効果. 心臓 46 : 32-39, 2014.
3) Piepoli MF, et al : Challenges in secondary prevention after acute myocardial infarction : A call for action. Eur J Prev Cardiol 23 : 1994-2006, 2016.
7) Takaya Y, et al : Impact of cardiac rehabilitation on renal function in patients with and without chronic kidney disease after acute myocardial infarction. Circ J 78 : 377-384. 2014.
9) 高橋将文 : 無菌性炎症とインフラマソーム. Organ Biology 20 : 244-245, 2013.
P.554 掲載の参考文献
1) 日本循環器学会, ほか : 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版).
2) Gruther W, et al : Muscle wasting in intensive care patients : ultrasound observation of the M. quadriceps femoris muscle layer. J Rehabil Med 40 : 185-189, 2008.
3) 日本集中治療医学会 早期リハビリテーション検討委員会 : 集中治療室における早期リハビリテーション~早期離床やベットサイドからの積極的運動に関する根拠に基づくエキスパートコンセンサス~, 2017年3月1日. [https://www.jsicm.org/pdf/soki_riha1609.pdf] (2018年9月閲覧)
4) Ozasa N, et al : Effects of machine-assisted cycling on exercise capacity and endothelial function in elderly patients with heart failure. Circ J 76 : 1889-1894, 2012.
7) Wosornu D, et al : A comparison of the effects of strength and aerobic exercise training on exercise capacity and lipids after coronary artery bypass surgery. Eur Heart J 17 : 854-863, 1996.
8) Takeyama J, et al : Effects of physical training on the recovery of the autonomic nervous activity during exercise after coronary artery bypass grafting : effects of physical training after CABG. Jpn Circ J 64 : 809-813, 2000.
9) Nakai Y, et al : Effects of physical exercise training on cardiac function and graft patency after coronary artery bypass grafting. J Thorac Cardiovasc Surg 93 : 65-72, 1987.
10) Goodman JM, et al : Central and peripheral adaptations after 12 weeks of exercise training in post-coronary artery bypass surgery patients. J Cardiopulm Rehabil 19 : 144-150, 1999.
12) 磯部光章, ほか : 2016年版 心臓移植に関する提言. 日本循環器学会, 2016.
P.559 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf]
2) 後藤剛 : TAVIの合併症とその対策. 心臓 46 : 432-438, 2014.
5) Rodes-Cabau J, et al : Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk : acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 55 : 1080-1090, 2010.
6) 志村徹郎, 山本真功 : わが国におけるTAVIの成績と今後の展望. 日本医事新報 4850 : 39-45, 2017.
7) Puri R, et al : TAVI or No TAVI : identifying patients unlikely to benefit from transcatheter aortic valve implantation, Eur Heart J 37 : 2217-2225, 2016.
10) Nishimura RA, et al : 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : e521-643, 2014.
11) Katz S, et al : Studies of illness in the aged. The index of adl : a standardized measure of biological and psychosocial function. JAMA 185 : 914-919, 1963.
12) 厚生労働省老健局老人保健課 : 基本チェックリストの考え方について, 2016. [https://www.mhlw.go.jp/topics/2007/03/dl/tp0313-1a-11.pdf]
13) 佐竹昭介 : 老年医学の展望 基本チェックリストとフレイル. 日本老年医学会雑誌 55 : 319-328, 2018.
P.565 掲載の参考文献
1) 日本循環器学会, ほか : 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版). 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告).
8) Bravo-Escobar R, et al : Effectiveness and safety of a home-based cardiac rehabilitation programme of mixed surveillance in patients with ischemic heart disease at moderate cardiovascular risk : A randomised, controlled clinical trial. BMC Cardiovasc Disord 17 : 66, 2017.
9) 今井優, ほか : 心疾患運動療法現場における安全性について. 臨床運動療法研究会誌 2 : 23-26, 2000.
P.572 掲載の参考文献
1) 筒井裕之, ほか : 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.asas.or.jp/jhfs/pdf/topics20180323.pdf]
2) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
10) Vital FM, et al : Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema. Cochrane Database Syst Rev (3) : CD005351, 2008.
12) 日本呼吸器学会NPPVガイドライン作成委員会 (編) : NPPV (非侵襲的陽圧換気療法) ガイドライン (改訂第2版), 南江堂, 2015.
13) Crane SD, et al : Randomised controlled comparison of continuous positive airways pressure, bilevel non-invasive ventilation, and standard treatment in emergency department patients with acute cardiogenic pulmonary oedema. Emerg Med J 21 : 155-161, 2004.
P.578 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.asas.or.jp/jhfs/pdf/topics20180323.pdf] (2018年12月閲覧)
2) 2018.1.24中央社会保険医療協議会 総会 (第386回), p256-258, 2018. [http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-lryouka/0000191963.pdf] (2018年12月閲覧)
3) O'Neill WM, et al : Hospital palliative care services : three models in three countries. J pain Symptom Manage 7 : 406-413, 1992.
4) World Health Organization : Pain Relief and Palliative Care. In : National Cancer Control Programmes : Policies and Managerial Guidelines, 2nd ed, p83-92, 2002.
5) Distribution of adults in need of palliative care at the end of life by disease groups. In : Global Atlas of Palliative Care at the End of Life, WPCA, 2014. [http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf] (2018年12月閲覧)
6) 緩和ケアの定義WHO Definition of Palliative Care. World Health Organization, Genova, Switzerland, 2002.
7) 循環器疾患の患者に対する緩和ケア提供体制のあり方について. [http://www.mhlw.go.jp/stf/shingi2/0000204785.html] (2018年10月閲覧)
9) NHS End of Life Care Programme publication supported by NCPC : Advance Care Planning : A Guide for Health and Social Care Staff. Advance Care Planning. pdf, 2007. (2018年12月閲覧)
10) 人生の最終段階における医療体制整備 アドバンス・ケア・プランニング. 在宅医療推進のための多職種合同研修会 [http://www.toyotachiiki-mc.or.jp/pageview/zaitaku_book/2018/02/001/html5.html#page=7] (2018年12月閲覧)
11) プラハ憲章 : The Prague Charter. [http://www.eapcnet.eu/Themes/Policy/PragueCharter.aspx] (2018年12月閲覧)
12) PEACEプロジェクトについて. [http://www.jspm-peace.jp/about/index.html] (2018年12月閲覧)
P.584 掲載の参考文献
1) Dumanovsky T, et al : The Growth of Palliative Care in U. S. Hospitals : A Status Report. J Palliat Med 19 : 8-15, 2016.
2) Rogers M, Dumanovsky T : How We Work : Trends and Insights in Hospital and Palliative Care, The Center to Advance Pallaitive Care and the National Palliative Care Research Center, New York, 2017.
3) Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 : e147-239, 2013.
4) Heart Failure Society of America ; Lindenfeld J, et al : HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 16 : e1-194, 2010.
5) McMurray JJ, et al : ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14 : 803-869, 2012.
6) Feldman D, et al : The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support : executive summary. J Heart Lung Transplant 32 : 157-187, 2013.
9) Commonly Asked Questions-Respecting Choices, 2018. [https://respectingchoices.org/how-canwe-help-you/commonly-asked-questions/], Accessed July 8th, 2018.
11) The Conversation Project, 2018. [https://theconversationproject.org/], Accessed July 8th, 2018.
14) Goldstein NE, et al : Comprehensive care for mechanical circulatory support : anew frontier for synergy with palliative care. Circ Heart Fail 4 : 519-527, 2011.
15) Gawande A : Being Mortal : Medicine and What Matters in the End, 1st ed, Metropolitan Books : Henry Holt & Company, New York, 2014.
P.589 掲載の参考文献
1) Hamaguchi S, et al : Body mass index is an independent predictor of long-term outcomes in patients hospitalized with heart failure in Japan. Circ J 74 : 2605-2611, 2010.
3) 衣笠良治, 山本一博 : 栄養介入で心不全悪化を予防する. 日本医事新報 4885 : 34-40, 2017.
5) Kinugasa Y, et al : Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 77 : 705-711, 2013.
7) 日本心不全学会ガイドライン委員会 (編) : 心不全患者における栄養評価・管理に関するステートメント, 2018. [http://www.asas.or.jp/jhfs/statement/]
8) 日本集中治療医学会重症患者の栄養管理ガイドライン作成委員会 : 日本版重症患者の栄養療法ガイドライン. 日本集中医療医学会雑誌 23 : 185-281, 2016.
9) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
12) Kinugasa Y, et al : Carnitine insufficiency is associated with adverse outcomes in patients with heart failure with preserved ejection fraction. J Aging Res Clin Practice 5 : 187-193, 2016.
16) Kinugasa Y, et al : Multidisciplinary intensive education in the hospital improves outcomes for hospitalized heart failure patients in a Japanese rural setting, BMC Health Serv Res 14 : 351, 2014.

XVII 心不全の予後

P.599 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2018年12月閲覧)
2) WRITING COMMITTEE MEMBERS : Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
3) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
6) Mebazaa A, et al : Acute heart failure and cardiogenic shock : amultidisciplinary practical guidance. Intensive Care Med 42 : 147-163, 2016.
18) Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) : The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction : an individual patient data meta-analysis. Eur Heart J 33 : 1750-1757, 2012.
20) Daniels LB, et al : Prognosis of stage A or B heart failure patients with elevated B-type natriuretic peptide levels. J Card Fail 16 : 93-98, 2010.
25) Gamble JM, et al : Patterns of care and outcomes differ for urban versus rural patients with newly diagnosed heart failure, even in a universal healthcare system. Circ Heart Fail 4 : 317-323, 2011.
27) Shiba N, et al : Emerging Problems of heart failure practice in Japanese women : lessons from the CHART study. Circ J 72 : 2009-2014, 2008.
28) Sakata Y, et al : Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan. Report from the CHART-2 study. Circ J 78 : 428-435, 2014.
P.607 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版).
2) Jacobson AF, et al : Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (Adre View Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 55 : 2212-2221, 2010.
3) 日本心不全学会ガイドライン委員会 (編) : 高齢心不全患者の治療に関するステートメント, 2016.
4) Gottlieb SS, et al : The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 8 : 136-141, 2002.
7) Smith GL, et al : Renal impairment and outcomes in heart failure : systematic review and metaanalysis. J Am Coll Cardiol 47 : 1987-1996, 2006.
11) Aaronson KD, et al : Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95 : 2660-2667, 1997.

XVIII 心不全の危険因子・予防

P.615 掲載の参考文献
1) McMurray JJ, et al : ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 : 1787-1847, 2012.
3) 大川真一郎, ほか : 弁膜症. 日本老年医学会雑誌 22 : 317-324, 1985.
4) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン 2017年版.
7) 斎藤能彦, ほか : 血中BNPやNT-proBNP値を用いた心不全診療の留意点について. [http://www.asas.or.jp/jhfs/topics/bnp201300403.html] (2019年1月閲覧)
8) Martins D, et al : The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults : data from NHANES III. J Gend Specif Med 4 : 10-13, 20, 2001.
15) 原田和昌 : 利尿薬を再考する-高齢者心不全におけるトラセミド (ルプラック) の意義-. 診療と新薬 51 : 1035-1047, 2014.
P.622 掲載の参考文献
1) 日本循環器学会 : 脳卒中と循環器病克服5カ年計画, 2016. [http://www.j-circ.or.jp/five_year/files/five_year_plan.pdf]
2) 日本循環器学会 : 心不全啓発のための「シン・シン (心臓・身体) 健康プロジェクト」 [http://www.j-circ.or.jp/topics/shinshin_prj.htm]
8) Lloyd-Jones DM, et al : Defining and setting national goals for cardiovascular health promotion and disease reduction : the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 121 : 586-613, 2010.
10) Chen J, et al : Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60 : 2504-2512, 2012.
11) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
P.629 掲載の参考文献
1) Page RL, et al : Drugs That May Cause or Exacerbate Heart Failure : A Scientific Statement From the American Heart Association. Circulation 134 : e32-69, 2016.
4) Zamorano JL, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016.
5) Fujiwara A, et al : Anthracycline antibiotics. Crit Rev Biotechnol 3 : 133-157, 1985.

最近チェックした商品履歴

Loading...